Skip to content
Research Article Open access CC BY 4.0

Convalescent Plasma Infusion does not Appear to Change the Prognosis in Italian Patients Hospitalized with Sars-Cov-2 Pneumonia

Gianluca Gessoni, Giovanni Roveroni, Lauretta Moro, Michela Pivetta, Michele Tessarin, Domenico Bagnara, Sara Valverde, Rossi Carla, Coluccia Enza, Collodel Luca, Roberto Valle, Giovanni Carretta

International Blood Research & Reviews · pp. 50–61 · Published 23 Mar 2023

10.9734/ibrr/2023/v14i2305

Abstract

Aims: This case-control prospective study aimed to describe the effects of COVID convalescent plasma (CCP) on late mortality in hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia.  Study Design: In this study were enrolled 214 consecutive patients with moderate to severe COVID-19 pneumonia hospitalized during the fourth trimester of 2020 in Venice Prefecture (North-East Italy). admitted to COVID-19 Hospitals of our district were enrolled. Methodology:  Confirmation of SARS-CoV-2 infection was made through reverse transcription-polymerase chain reaction test in nasopharyngeal swabs. The severity of each patient’s clinical condition was determined considering the Berlin score radiological findings and ventilatory data.  Clinical data, risk factors and comorbidity, laboratory test reports and imaging diagnosis of all patients were recorded at hospitalization.   In Italy, during the fourth trimester 2020 standard therapy for COVID-19 Pneumonia was: NSAIDs, ventilator support, LMWH, steroids, antibiotics and antiviral drugs; 108 patients received standard therapy alone and 106 received standard therapy in combination with CCP. The endpoint was mortality at 30 days. Results: Patients series were comparable for gender, age, comorbidity and risk factors, Berlin score, PaO2/FiO2. Data concerning radiological findings and data concerning ventilatory support suggested a higher severity of patients treated with standard therapy plus CCP.  Mortality rate at 30 days was 30.6% among subjects treated with standard therapy versus 30.2% among                      subjects treated with standard therapy plus CCP. The mortality observed in the two groups did not differ significantly. In the present study, however, we observed a higher mortality than reported in the literature. This result may be attributable to the greater severity of the patients considered. Conclusions: This case-control prospective study showed that in a cohort of hospitalized patients suffering from severe 19 pneumonia, the addition of CCP to the standard therapy did not impact the mortality rate at 30 days. However, we believe that further studies are needed to evaluate the effectiveness of convalescent plasma therapy.

COVID-19 Serotherapy Mortality Pneumonia Risk factors

References (29)

  1. 1 Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma [DOI]
  2. 2 Effectiveness of convalescent plasma therapy in severe COVID-19 patients [DOI]
  3. 3 The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? [DOI]
  4. 4 Potential interventions for novel coronavirus in China: A systematic review [DOI]
  5. 5 Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes [DOI]
  6. 6 Predictors of mortality in hospitalized COVID‐19 patients: A systematic review and meta‐analysis [DOI]
  7. 7 Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea [DOI]
  8. 8 Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19 [DOI]
  9. 9 Insight into 2019 novel coronavirus — An updated interim review and lessons from SARS-CoV and MERS-CoV [DOI]
  10. 10 Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis [DOI]
  11. 11 Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial [DOI]
  12. 12 Drug Evaluation during the Covid-19 Pandemic [DOI]
  13. 13 A Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Signals [DOI]
  14. 14 COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes [DOI]
  15. 15 Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic [DOI]
  16. 16 COVID-19 convalescent plasma [DOI]
  17. 17 Operational protocol for donation of anti‐COVID‐19 convalescent plasma in Italy [DOI]
  18. 18 Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2 [DOI]
  19. 19 Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis [DOI]
  20. 20 How Safe Is COVID-19 Convalescent Plasma? [DOI]
  21. 21 Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis [DOI]
  22. 22 Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19 [DOI]
  23. 23 Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study [DOI]
  24. 24 High-Dose Convalescent Plasma for Treatment of Severe COVID-19 [DOI]
  25. 25 Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps [DOI]
  26. 26 Failure of plasma therapy in Covid-19 [DOI]
  27. 27 Convalescent Plasma for COVID-19. A randomized clinical trial [DOI]
  28. 28 The Prevalence of Comorbidities and Their Association with Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis [DOI]
  29. 29 Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

52

Page views

0

PDF downloads

27

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.